Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nasal spray could prevent migraines without drugs

NCT ID NCT07100496

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a nasal spray called MIG-SPRAY for preventing migraines in 45 adults aged 18-55. The spray forms a protective film inside the nose to possibly stop migraine triggers. Participants use it three times daily for three months, and researchers track side effects and migraine frequency compared to a control group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MIG-SPRAY (a film-forming liquid nasal spray, classified as a medical device)
What this could lead to
If it works, this could offer a new, non-drug option for preventing migraines with fewer side effects.
What could go wrong
This is a small, early-phase trial focused on safety, not effectiveness. The device may not reduce migraines significantly, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 55 years * Migraine diagnosis for \>1 year * Meeting ICHD-3 (International Classification of Headache Disorders 3rd edition, code 1.1) diagnostic criteria * Effective contraception for females of childbearing potential * Sufficient cooperation and understanding to comply with trial requirements * Provided informed consent after receiving complete study information * Enrolled in the French Social Security system Exclusion Criteria: * Hypersensitivity: Known allergy to any component of the investigational product(s), salicylates, or camphor. * Substance abuse: Current drug dependence or abuse (investigator's judgment). * Pregnancy/breastfeeding: Pregnant or lactating women. * Concurrent trials: Participation in another clinical trial, ongoing exclusion period, or receipt of \>€6000 in trial-related compensation in the past 12 months. * Legal protections: Under legal guardianship, curatorship, or deprivation of liberty. * Medical incompatibility: Any condition deemed unsafe for participation (investigator's assessment). * Significant medical history: Relevant comorbidities or antecedents (investigator's discretion).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • CHU de Clermont-ferrand

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.